Preclinical News and Research

RSS

Bioscience fund GBS invests US$6m in Xenome

Biopharmaceutical company Xenome Limited today announced it has received a convertible note placement of US$6 million from GBS Venture Partners, a Melbourne based life sciences specialist that invests in unlisted and listed high growth companies involved in innovative technologies.

23 Jul 2008

Potentially new biomarkers for Alzheimer's

Every aging baby boomer listens for the footsteps of Alzheimer's, and for good reason: It's estimated that 10 million American boomers will develop the disease. The need to develop preventative strategies, ideally long before Alzheimer's destructive, clinical symptoms appear, is critical.

19 Jul 2008

Turning on hormone tap could aid osteoporosis fight

A potential new drug that 'opens the taps' for the release of useful hormones could stimulate new bone growth - and may eventually bring relief to osteoporosis sufferers.

From The University of Manchester 16 Jul 2008

Neuron to publish Prana's PBT2 preclinical research on Alzheimer's disease

Prana Biotechnology Ltd. has announced the publication of key research findings with its lead Alzheimer's Disease drug, PBT2.

10 Jul 2008

Combining medical knowledge to save lives

Cardiovascular disease (CVD) is the biggest killer among chronic diseases, claiming 17 million lives globally every year. Yet doctors can only attribute 50% of cardiovascular diseases to known risk factors.

9 Jul 2008

Eli Lilly to buy SGX Pharmaceuticals

Eli Lilly and Company and SGX Pharmaceuticals, Inc. today announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction. SGX, based in San Diego, California, is a biotechnology company focused on drug discovery and development in the area of oncology.

8 Jul 2008

Body's own 'marijuana' is good for the skin

Scientists from Hungary, Germany and the U.K. have discovered that our own body not only makes chemical compounds similar to the active ingredient in marijuana (THC), but these play an important part in maintaining healthy skin

2 Jul 2008

Curbing kids' risk-taking behavior

Educating kids and their parents about the importance of wearing a helmet when riding a bike, and buckling up and riding in the back seat of the car, could help to cut down the more than 30 million injury-related emergency room visits that occur each year in the United States.

1 Jul 2008

Hydrogen sulfide significantly improves survival after extreme blood loss

For the first time, researchers have demonstrated that the administration of minute amounts of inhaled or intravenous hydrogen sulfide, or H2S - the molecule that gives rotten eggs their sulfurous stench - significantly improves survival from extreme blood loss in rats.

1 Jul 2008

New device blocks stomach nerve signals - alternative to existing bariatric surgeries

A new implantable medical device, developed in collaboration with Mayo Clinic researchers, shows promise as a reversible and less extreme alternative to existing bariatric surgeries, according to findings published in the current issue of the journal Surgery.

26 Jun 2008

New clinical trial for patients with asbestos-associated lung cancer

The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is now recruiting patients for a clinical research study of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung's lining that is almost always caused by previous exposure to asbestos.

26 Jun 2008

Transplants of mononuclear human umbilical cord blood may help Lou Gehrig's patients

A study at the University of South Florida has shown that transplants of mononuclear human umbilical cord blood (MNChUCB) cells may help patients suffering from Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

24 Jun 2008

Early detection of Alzheimer's in the pipeline

A boost of $1.6 million for new research into Alzheimer's Disease for Australian scientists means that the early detection of the disease could well be in the pipeline.

19 Jun 2008

Peregrine Pharmaceuticals awarded two new U.S. patents for targeted anti-aminophospholipid agents

Peregrine Pharmaceuticals, Inc. today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents.

16 Jun 2008

EntreMed receives new patent for 2-Methoxyestradiol analogs

EntreMed, Inc. has announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2- methoxyestradiol (2ME2).

11 Jun 2008

Maxygen receives approval for trial of factor VIIa in UK

Maxygen, Inc. today announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United Kingdom to initiate a first-in-human Phase I trial of MAXY-VII in hemophilia patients.

11 Jun 2008

Synthetic molecules developed by Hebrew University researchers hold promise for new family of anti-cancer drugs

Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.

4 Jun 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

3 Jun 2008

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

3 Jun 2008